Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsBertrand Routy, Laurence Zitvogel, Vichnou Poirier-Colame et al.|Science|2017Cited by 5.4k
Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung CancerMiguel García-Pardo, Natasha B. Leighl, Kasia Czarnecka‐Kujawa et al.|JAMA Network Open|2023Cited by 60
Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiologyJuan Carlos Laguna, Laura Mezquita, Miguel García-Pardo et al.|Therapeutic Advances in Medical Oncology|2024Cited by 48
Vaccine Therapy in Non-Small Cell Lung CancerMiguel García-Pardo, Laura Mezquita, Teresa Gorría et al.|Vaccines|2022Cited by 23
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic reviewRita Leporati, Laura Mezquita, Édouard Auclin et al.|Therapeutic Advances in Medical Oncology|2024Cited by 6